ONCC Certification Test Results Are Announced

January 1, 2002

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 11 No 1

Volume 11

Issue 1

PITTSBURGH-The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.

PITTSBURGHThe Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.

Of nearly 3,000 nurses who took the Oncology Certified Nurse (OCN) test, 2,503 (85%) passed, including 1,409 who were newly certified and 1,094 who renewed their credential.

More than 300 registered nurses took the Certified Pediatric Oncology Nurse (CPON) examination, and 244 (77%) passed, 150 who were newly certified and 94 who renewed their CPON certification.

Articles in this issue

ODAC Sends Mixed Message on New Gliadel Wafer Indication

ONCC Certification Test Results Are Announced

Rituximab Ups Survival in Aggressive and Indolent NHL

Topotecan Used in Aggressive Front-Line Therapy for SCLC

Depsipeptide Shows Activity in T-Cell Lymphoma

FDG-PET Useful in Newly Diagnosed and Recurrent NSCLC

Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trial

ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insert

FDA and VA Plan Joint AIDS Study

Breast Conservation Increases With On-Site Radiation Unit

Washington State Hikes Cigarette Tax

Moffitt’s Diet Guidelines for Immunocompromised Patients

AMA Approves New CPT Code for Serum HER-2 Test

NCI Formalizes Role of Advocates

Better Prognosis for Outer Quadrant Breast Cancers

Related Videos

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

video 8 - "Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations"

Video 7 - "Second-Line Treatment of Patients With EGFR-Mutated NSCLC"

A panel of 5 experts on liver cancer

A panel of 5 experts on liver cancer

A panel of 5 experts on liver cancer

Related Content

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

Higher Mortality Risk Reported in Cancer Surgery During COVID-19 Pandemic

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

Investigators Discontinue Vibostolimab Combo in Resected Melanoma Trial

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

Nivolumab ± Ipilimumab Yields Durable Responses in Cervical Cancer

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

Related Content

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

Higher Mortality Risk Reported in Cancer Surgery During COVID-19 Pandemic

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

Investigators Discontinue Vibostolimab Combo in Resected Melanoma Trial

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

Nivolumab ± Ipilimumab Yields Durable Responses in Cervical Cancer

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.